CMR Surgical closed a financing round of more than $200 million to accelerate commercial expansion of the Versius Surgical Robotic System to more hospitals around the world – with a major focus on launching it in the United States – and to continue advancing surgical robotics and product development, including the launch of the newly enhanced Versius Plus.
The company said Versius has been used to complete more than 30,000 surgical cases globally in more than 30 different countries across a wide range of specialities including colorectal, general, gynaecology, thoracic and urology surgeries.
CMR is also actively expanding its clinical footprint with two ongoing clinical trials: a pioneering paediatrics study, which is the world’s first multicentre prospective trial on the use of Versius in paediatric surgery, and a transoral robotic surgery (TORS) trial, further demonstrating the versatility and capability of Versius in new surgical applications.
“CMR is a competitive, well-established company with a transformative product providing clear clinical value. We are now at a pivotal stage, poised to capitalise on significant opportunities for market expansion, including in the U.S., while continuing to penetrate deeper into existing markets," said CEO Massimiliano Colella.
